He holds a degree in Economics and Business Administration from the University of Zaragoza and a PhD in Economics from the Autonomous University of Barcelona. He is Professor of the Foundations of Economic Analysis at the UNED, where he was Director of the International PhD School and where he currently coordinates the Doctoral Programme in Economics and Business. He was Director General of the Institute of Fiscal Studies and Director of the FEDEA-BBVA Chair of New Consumers at the Foundation for Applied Economics Studies. He is currently an Affiliate Researcher at Economics for Energy. The areas in which he has developed his research include the analysis of the behaviour of individuals in consumer decisions and job offers, as well as in the simulation and evaluation of the effects of public policies. He has been and is a Member of the Scientific Committee or of the Advisory Committee or Editor of several academic journals and he has published the results of his research in national and international journals in his specialty.
Bruno Vellas is chair of the Gerontopole & Department of Geriatric Internal Medicine at the Toulouse University Hospital and is member of INSERM UMR 1027, chair of the WHO Collaborating Center for Frailty, Clinical Research and Geriatric Training. He is of Chairman of the Scientific Committee of the plan Grand Age (National French Plan on Ageing). He studied medicine in Toulouse and received the degree of Doctor of Medicine in 1987 and a PhD in Pysiopathology in 1990. He had a doctoral training in nutrition and aging at the University of New Mexico, USA, Clinical Nutrition Lab, School of Medicine from 1987 to 1988. His main interests are: development of aging and geriatric clinical research and care. His research and care has been supported by several European, national and international research grants. He is the founder of the Gerontopole to develop innovation and research for older adults. He is the author and co-author of more than 858 publications in peer review journals since 1987, Index H: 81. He serves as editor, editorial committee member and reviewer of several major journals. He is adjunct professor at the Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA and is member of the scientific advisory board of several major scientific institutions in France, EU, Japan and the US. Since 2016, he is titular member of the French National Academy of Medicine, Officier de la Légion d’Honneur, and was recipient of the Palmes Académiques in 2016. He is the past president of the IAGG (International Association of Gerontology and Geriatrics) a NGO with a seat at the United Nations, and the founder of the EADC (European Alzheimer’s Disease Consortium), the CTAD (Clinical Trial in Alzheimer’s Disease conference) and the ICFSR (International Conference for Frailty and Sarcopenia Research). He is the chair of the WHO Collaborating Center for Frailty, Clinical Research and Geriatric Training since september 2017 and principal investigator on the INSPIRE Project on Geroscience.
Graduate in Biology and PhD in Physiology from the University of Murcia. He worked for four years in the Molecular Nutrition Group of the Institute of Aquaculture at the University of Stirling (Scotland, United Kingdom) thanks to an extension grant for postdoctoral studies abroad from the Ramón Areces Foundation and an Intra-European Marie Curie grant to develop new fish models for the study of ageing, particularly the circadian system of these animals. He has been working since 2017 as a researcher in the Chronobiology Group of the University of Murcia on a project to understand the mechanisms associated with the ageing of the circadian system of vertebrate models (fish of the Nothobranchius genus), which connects environmental light, melatonin and the lipids that make up cell membranes, particularly mitochondria.
Carlos F. Sánchez-Ferrer
Carlos Félix Sánchez Ferrer studied Medicine at the Universidad Autónoma de Madrid (UAM), where he graduated in 1981 and received his PhD in 1984. Having been awarded scholarships from the Spanish Health Research Fund (FIS) and the Mayo Foundation, he held a postdoctoral position during 1987 at the Mayo Clinic and Mayo Medical School (Dept. of Physiology), followed by another at the Medical College of Wisconsin (Dept of Physiology) thanks to an International Research Fellowship of the Fogarty International Center (National Institutes of Health, USA). He was a Lecturer in Pharmacology between 1987 and 2005 and has been Professor of this subject since 2005, always in the Department of Pharmacology and Therapeutics of the UAM. He has been the Director of this Department since 2013. He was Vice Dean of Research of the Faculty of Medicine of the UAM between 2000 and 2007 and has been Correspondent Academic of the National Royal Academy of Medicine of Spain since 2002. Together with Prof. Peiró, he leads a UAM and IdiPAZ research group named with the acronym FARMAVASM, dedicated to the study of the mechanisms that produce deterioration of the vascular function in pathological conditions, such as diabetes mellitus and obesity, as well as the analysis of the underlying cellular and molecular mechanisms of vascular aging. As pharmacologists, a fundamental aim of the group is to characterise new therapeutic targets that make it possible to prevent or delay vascular aging, using for this purpose different experimental approaches, from human vascular cell cultures to animal models and patient studies. He collaborates with various prestigious national and foreign researchers and has authored more than one hundred scientific publications in international journals, the majority in the first quartile. He has co-directed 18 doctoral theses and has been the lead researcher on 25 competitive projects at regional, national and international level.
He is a co-founder and CEO at Senolytic Therapeutics Inc., a pharmaceutical company that develops a novel class of medicines by targeting senescence cells. He is also supporting investments and strategic partnerships at Life Biosciences Inc. in Europe. Currently, Marc is a strategic advisor at Ninevah Therapeutics, Cebiotex, Retinset Therapeutics and Origen Ventures. He is a co-founder and Partner at Chasing Science, an early-stage biomedical venture builder. Marc is also a founder and Advisor at Tech & Business Innovation (TBI), an academic firm focused on knowledge exchange and corporate-academic partnerships. Marc brings experience as advisor and board member for multiple organizations and as co-founder of several companies. Marc has implemented Entrepreneurs-in-Residence programs at several academic institutions such as IRB Barcelona. From 2010 to 2012, Marc was working for Isis Innovations/University of Oxford as an associate consultant in Spain and LATAM. From 2007 to 2011, Marc was working at Endor, a nanomedicine company based in Spain. During this period, he was R&D director (drug-delivery nano-systems for cancer therapy) and Business Development Director (launched several nanotechnology products to the cosmetic and textile markets).
Previously, Marc also worked in the pharmaceutical environment in Novartis. He also collaborated with other research institutions such as Cancer Research UK and Boston College during his academic career. Marc gained a DPhil in Biochemistry from the University of Oxford in 2006, and a Harvard Business School PLD Program in 2011. Marc also gained a M.Sc. in Chemical Engineering in 2001 and a B.Sc. in Chemistry from IQS (Barcelona) in 2000.
Manuel Serrano obtained his PhD in 1991, from the Universidad Autónoma de Madrid. From 1991 to 1996, Serrano worked in the team of David Beach in Cold Spring Harbor Laboratory, NY. During this period, Serrano made his most important discovery with the identification and characterization of the gene p16, one of the most important genes for anti-cancer protection. Serrano returned to Spain in 1997 to lead a research group, first at the National Center of Biotechnology (CNB), and then, from 2003 to 2017, at the Spanish National Cancer Research Center (CNIO), both in Madrid. In 2017, Serrano moved to the Institute for Research in Biomedicine (IRB), in Barcelona.
Manuel Serrano is internationally recognized in the field of tumor suppression. In addition to the discovery of p16, one of his main discoveries has been the identification of cellular senescence as a main anti-oncogenic response. Recently, his laboratory has also shown that cellular senescence participates in several tissue remodeling processes during embryo development. The Serrano team was pioneer in the generation of genetically-modifed mice resistant to cancer and found a link between tumor suppressor genes and aging.
In recent years, the research interests of Manuel Serrano have extended to metabolism and cellular reprogramming in relation to aging. The Serrano laboratory was first in demonstrating that cellular reprogramming into pluripotency is possible within an organism, and this discover was considered Advance of the Year 2013 by Nature Medicine. More recently, Serrano has reported in Science that in vivo reprogramming is enhanced by the coexistence of tissue injury thanks to the production of the interleukin IL-6. The focus of his laboratory is now to apply their knowledge on senescence and reprogramming to degenerative diseases such as lung, kidney and heart fibrosis.
Manuel Collado holds a PhD in Biology from the Universidad Autónoma de Madrid. Having previously worked in London, New York and at the Spanish National Cancer Research Centre (CNIO) in Madrid, he is currently the Miguel Servet Researcher at the Health Research Institute of Santiago de Compostela (IDIS) where he manages the Cancer and Aging Stem Cell Laboratory. He publishes information on biomedical research into aging in the blog “Fuente de la Eterna Juventud”
Reason is co-founder and CEO of Repair Biotechnologies, Inc. He is the founder and writer of Fight Aging!, a leading blog in the longevity biotech community founded in 2002. Reason is also an active angel investor in longevity startups. Repair Biotechnologies, Inc. is a biotechnology company with the mission to develop and bring to the clinic therapies that significantly improve human healthspan through targeting the causes of age-related diseases and aging itself. Founded in 2018, Repair Biotechnologies is developing therapies with the goals of regenerating the thymus, treating cancer, and reversing atherosclerosis.
Born in 1953, José Viña is Professor of Physiology at the University of Valencia. He obtained his PhD at Valencia University in 1976 and has honoris causa doctorates from the University of Rennes (France) and the University of Buenos Aires (Argentina). Once he had finished his degree in Medicine at the University of Valencia in 1974, José Viña started biomedical investigation at the Medical Research Council of the University of Oxford, which at that time was run by the Nobel Laureate, Hans Krebs. Subsequently, he worked as professor of Physiology at the University of Extremadura. In 1984, he was designated professor at the Department of Physiology of the University of Valencia. He has published over 330 international papers and has received several honours, including the Albert Struyvenberg medal awarded by the European Society for Clinical Investigation (ESCI) 2017, for leadership in research in ageing and exercise. He is also the author of the book “Cuídese hoy para que no le cuidemos mañana: cómo vivir para envejecer mejor” (2009). José Viña specialises in nutrition and exercise and their application in healthy ageing. He has been leading a successful research group dealing with nutritional aspects, with longevity and, more recently, with frailty and Alzheimer’s disease.
Manuel Perez Alonso
He holds a PhD in Biology and he is a Professor of Genetics at the University of Valencia. His research focuses on molecular genetics and genomic applied to medicine. He is known for his outreach work. He is the author of more than 50 research papers on his field of expertise, including three articles published by the prestigious journal Nature. As a scientific entrepreneur, he is a founding partner of the company Sistemas Genómicos (Genomic Systems), Valentia BioPharma and the Genomic Medicine Institute, among others.